Detection of quantitative trait loci affecting caffeine metabolism by interval mapping in a genome-wide scan of C3H/HeJ x APN F2 mice

Drug Metabolism and Disposition

Volumn 27, Issue 12, 1999, Pages 1375-1380

  Casley, William L ^a,b   Menzies, J Allan ^a   Whitehouse, Larry W ^a   Moon, Thomas W ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b Banting Research Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

8 CHLOROTHEOPHYLLINE; CAFFEINE; DNA;

ANIMAL EXPERIMENT; ARTICLE; CHROMOSOME 1; CHROMOSOME 9; DRUG METABOLISM; FEMALE; GENE LOCUS; GENETIC POLYMORPHISM; GENOME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INBRED STRAIN; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUANTITATIVE TRAIT;

ANIMALS; BREEDING; CAFFEINE; CHROMOSOME MAPPING; CYTOCHROME P-450 CYP1A2; FEMALE; GENETIC MARKERS; GENOTYPE; MALE; MICE; MICE, INBRED C3H; MULTIFACTORIAL INHERITANCE; PHENOTYPE; QUANTITATIVE TRAIT, HERITABLE; SEX FACTORS; THEOPHYLLINE;

EID: 0032701319     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Blake JA, Eppig JT, Richardson JE and Davisson MT (1998) The mouse genome database (MGD): A community resource. Status and enhancements. The Mouse Genome Informatics Group. Nucleic Acids Res 26:130-137.
2. Buters JT, Tang BK, Pineau T, Gelboin HV, Kimura S and Gonzalez FJ (1996) Role of CYP1A2 in caffeine pharmacokinetics and metabolism: Studies using mice deficient in CYP1A2. Pharmacogenetics 6:291-296.
3. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, Teitel CH, Massengill JP, Lawsen MF and Kadlubar FF (1992) Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 2:116-127.
4. Casley WL, Menzies JA, Girard M, Larocque L, Mousseau N, Whitehouse LW and Moon TW (1997b) Differences in caffeine 3-demethylation activity among inbred mouse strains: A comparison of hepatic Cyp1a2 gene expression between two inbred strains. Fundam Appl Toxicol 40:228-237.
5. Casley WL, Menzies JA, Mousseau N, Girard M, Moon TW and Whitehouse LW (1997a) Increased basal expression of hepatic Cyp1a1 and Cyp1a2 genes in inbred mice selected for susceptibility to acetaminophen-induced hepatotoxicity. Pharmacogenetics 7:283-293.
6. Corcos L, Marc N, Wein S, Fautrel A, Guillouzo A and Pineau T (1998) Phenobarbital induces cytochrome P4501A2 hnRNA, mRNA and protein in the liver of C57BL/6J wild type and aryl hydrocarbon receptor knock-out mice. FEBS Lett 425:293-297.
7. Dietrich WF, Miller J, Steen R, Merchant MA, Damron-Boles D, Husain Z, Dredge R, Daly MJ, Ingalls KA, O'Connor TJ, Evans CA, DeAngelis MM, Levinson DM, Kruglyak L, Goodman N, Copeland NG, Jenkins NA, Hawkins TL, Stein L, Page DC and Lander ES (1996) A comprehensive genetic map of the mouse genome. Nature (Lond) 380:149-152.
8. Fernandez-Salguero P, Pineau T, Hilbert DM, McPhail T, Lee SS, Kimura S, Neben DW, Rudikoff S, Ward JM and Gonzalez FJ (1995) Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science (Wash DC) 268:722-726.
9. Fuhr U and Rost KL (1994) Simple and reliable CYP1A2 phenotyping by the paraxanthine/ caffeine ratio in plasma and in saliva. Pharmacogenetics 4:109-116.
10. Grant DM, Tang BK, Campbell ME and Kalow W (1986) Effect of allopurinol on caffeine disposition in man. Br J Clin Pharmacol 21:454-458.
11. Grant DM, Tang BK and Kalow W (1984) A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol 17:459-464.
12. Gu L, Gonzalez FJ, Kalow W and Tang BK (1992) Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 2:73-77.
13. Huang JD, Guo WC, Lai MD, Guo YL and Lambert GH (1999) Detection of a novel cytochrome P-450 1A2 polymorphism (F21L) in Chinese. Drug Metab Dispos 27:98-101.
14. Kalow W and Tang BK (1991) Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 50:508-519.
15. Kalow W and Tang BK (1993) The use of caffeine for enzyme assays: A critical appraisal. Clin Pharmacol Ther 53:503-514.
16. Kimura S and Nebert DW (1986) cDNA and complete amino acid sequence of mouse P2(450): Allelic variant of mouse P3(450) gene. Nucleic Acids Res 14:6765-6766.
17. Kimura S, Gonzalez FJ and Nebert DW (1986) Tissue-specific expression of the mouse dioxin-inducible P(1)450 and P(3)450 genes: Differential transcriptional activation and mRNA stability in liver and extrahepatic tissues. Mol Cell Biol 6:1471-1477.
18. Lander ES and Botstein D (1989) Mapping Mendelian factors underlying quantitative traits using RFLP linkage maps. Genetics 121:185-199.
19. Lander ES, Green P, Abrahamson J, Barlow A, Daly MJ, Lincoln SE and Newburg L (1987) MAPMAKER: An interactive computer package for constructing primary genetic linkage maps of experimental and natural populations. Genomics 1:174-181.
20. Lander E and Kruglyak L (1995) Genetic dissection of complex traits: Guidelines for interpreting and reporting linkage results. Nat Genet 11:241-247.
21. Lelo A, Birkett DJ, Robson RA and Miners JO (1986) Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. Br J Clin Pharmacol 22:177-182.
22. Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF and Kamataki T (1994) Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: Absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev 3:413-421.
23. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M and Kamataki T (1999) Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: Effect on the CYP1A2 inducibility in humans. J Biochem 125:803-808.
24. Olesen OV and Linnet K (1997) Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab Dispos 25:740-744.
25. Paterson AH, Lander ES, Hewitt JD, Peterson S, Lincoln SE and Tanksley SD (1988) Resolution of quantitative traits into Mendelian factors by using a complete linkage map of restriction fragment length polymorphisms. Nature (Lond) 335:721-726.
26. Peirce JL, Derr R, Shendure J, Kolata T and Silver LM (1998) A major influence of sex-specific loci on alcohol preference in C57BL/6 and DBA/2 inbred mice. Mamm Genome 9:942-948.
27. Poland A and Glover E (1973) Chlorinated ditenzo-p-dioxins: Potent inducers of delta-aminolevulinic acid synthetase and aryl hydrocarbon hydroxylase. II. A study of the structure-activity relationship. Mol Pharmacol 9:736-747.
28. Rostami-Hodjegan A, Nurminen S, Jackson PR and Tucker GT (1996) Caffeine urinary metabolite ratios as markers of enzyme activity: A theoretical assessment. Pharmacogenetics 6:121-149.
29. Ryu DY, Levi PE, Fernandez-Salguero P, Gonzalez FJ and Hodgson E (1996) Piperonyl butoxide and acenaphthylene induce cytochrome P450 1A2 and 1B1 mRNA in aromatic hydrocarbon-responsive receptor knock-out mouse liver. Mol Pharmacol 50:443-446.
30. Sachse C, Brockmöller J, Bauer S and Roots I (1999) Functional significance of a C-A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47:445-449.
31. Sesardic D, Pasanen M, Pelkonen O and Boobis AR (1990) Differential expression and regulation of members of the cytochrome P4501A gene subfamily in human tissues. Carcinogenesis 11:1183-1188.
32. Shimada T, Martin MV, Pruess-Schwartz D, Marnett LJ and Guengerich FP (1989) Roles of individual human cytochrome P-450 enzymes in the bioactivation of benzo(a)pyrene, 7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene, and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons. Cancer Res 49:6304-6312.
33. Spatzenegger M and Jaeger W (1995) Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab Rev 27:397-417.
34. Tang BK, Zhou Y, Kadar D and Kalow W (1994) Caffeine as a probe for CYP1A2 activity: Potential influence of renal factors on urinary phenotypic trait measurements. Pharmacogenetics 4:117-124.
35. Tarrus E, Cami J, Roberts DJ, Spickett RG, Celdran E and Segura J (1987) Accumulation of caffeine in healthy volunteers treated with furafylline. Br J Clin Pharmacol 23:9-18.
36. Tassaneeyakul W, Birkett DJ, McManus ME, Veronese ME, Andersson T, Tukey RH and Miners JO (1994) Caffeine metabolism by human hepatic cytochromes P450: Contributions of 1A2, 2E1 and 3A isoforms. Biochem Pharmacol 47:1767-1776.
37. Taylor BA and Phillips SJ (1996) Detection of obesity QTLs on mouse chromosomes 1 and 7 by selective DNA pooling. Genomics 34:389-398.
38. Vistisen K, Poulsen HE and Loft S (1992) Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine. Carcinogenesis 13:1561-1568.
39. West DB, Waguespack J, York B, Goudey-Lefevre J and Price RA (1994) Genetics of dietary obesity in AKR/J × SWR/J mice: Segregation of the trait and identification of a linked locus on chromosome 4. Mamm Genome 5:546-552.
40. Wright S (1968) Evolution and the genetics of populations, in Genetic and Biometric Foundations vol 1, pp 373-420, University of Chicago Press, Chicago.